Pharma major Lupin announces launch of its diagnostics business
Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.
Lupin Diagnostics, a wholly-owned subsidiary of the company, has formally commenced operations in the country, Lupin said in a regulatory filing.
The company said it has established a 45,000 sq ft National Reference Laboratory in Navi Mumbai. The core facilities of the laboratory include all major diagnostics services, preventive health checkups, and a comprehensive range of tests.
All the processing will be operated by Lupin Healthcare as a hub and will be connected to a nation-wide network of regional, satellite and collection centers. In addition, Lupin is identifying franchisee partners for the initiative, it added.
Commenting on the development, Lupin Managing Director Nilesh Gupta said, “combining decades of experience and knowledge in the field of therapeutics, we aim to provide our doctors, patients and consumers with the same experience offering quality diagnostic services that are built on trust.”
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology and immunology, among others, the filing said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
